Evaluation of Persistence of Immunogenicity Following an Open-labelled, Randomized Controlled Trial Evaluating Non-inferiority of 1+1 Compared to 2+1 Dosing Schedules of 10-valent and 13-valent Pneumococcal Conjugate Vaccine in South Africa

This study will evaluate the persistence of immunogenicity following a reduced dosing schedule of 10- or 13-valent Pneumococcal Conjugate Vaccine (PCV10, PCV13). This is the follow-up of a randomized controlled trial in which children received a single priming dose of PCV10 or PCV13 (at 6 or 14 weeks of age) followed by booster dose at 9 months of age (1+1 schedule), compared to a 2+1 PCV schedule (6, 14 weeks of age and 9 months of age).

Start Date14 Feb 2020

Sponsor / Collaborator

University of the Witwatersrand

NCT03489018

/ CompletedPhase 4IIT

The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines (PCV10 and PCV13) on Immunogenicity and Vaccine-serotype Carriage in Kenyan Infants

Before the introduction of pneumonia vaccines in 2000, between 700,000 - 1 million children died each year as a result of infection with the bacteria Streptococcus pneumoniae and the resulting diseases, namely, meningitis, sepsis and pneumonia. Most of the deaths were in Africa and Asia. Where the vaccines have been introduced, they have been highly effective and have already reduced disease. However, at 10 USD per child, they are not affordable to most low-income countries without financial support from Gavi, the Vaccine Alliance.
This project aims to assess whether lower doses of the two commercially available pneumonia vaccines can protect Kenyan infants as well as the full dose. The results could be used to increase the affordability of the pneumonia vaccine, and enable delivery of the vaccine to continue in the absence of Gavi support.

Start Date21 Mar 2019

Sponsor / Collaborator

London School of Hygiene & Tropical Medicine

[+4]

NCT03547271

/ CompletedPhase 3

Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe

Primary objective:
This study aimed to demonstrate the non-inferiority of the antibody response against meningococcal serogroups A, C, Y, and W following the administration of a 3-dose series of MenACYW conjugate vaccine compared to a 3-dose series of a licensed meningococcal vaccine when each vaccine was given concomitantly with routine pediatric vaccines (10-valent pneumococcal vaccine and diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and Haemophilus influenzae type b [DTaP-IPV-HB-Hib vaccine]) to infants and toddlers 6 weeks to 18 months old
Secondary objectives:
This study aimed to demonstrate the non-inferiority of the antibody (Ab) response against meningococcal serogroups A, C, Y, and W following the administration of 2 doses in infancy of MenACYW conjugate vaccine compared to 2 doses of a licensed meningococcal vaccine when each vaccine was given concomitantly with routine pediatric vaccines (10-valent pneumococcal vaccine and DTaP-IPV-HB-Hib vaccine) to infants and toddlers 6 weeks to 18 months old.
- This study aimed to describe the Ab responses against meningococcal groups A, C, Y, and W and the antigens of the routine pediatric vaccines administered in the study.

Start Date14 Dec 2018

Sponsor / Collaborator

Sanofi Pasteur SA

100 Clinical Results associated with Pneumococcal Polysaccharide Conjugate Vaccine(Glaxosmithkline Plc)

100 Translational Medicine associated with Pneumococcal Polysaccharide Conjugate Vaccine(Glaxosmithkline Plc)

100 Patents (Medical) associated with Pneumococcal Polysaccharide Conjugate Vaccine(Glaxosmithkline Plc)

505

Literatures (Medical) associated with Pneumococcal Polysaccharide Conjugate Vaccine(Glaxosmithkline Plc)

31 Dec 2026·Human Vaccines & Immunotherapeutics

Effectiveness of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PCV10) against hypoxic pneumonia in children in Maha Sarakham Province, Thailand

Article

Author: Unrit, Kengkaj ; Deeraksa, Supasin ; Kosalaraksa, Pope ; Chokephaibulkit, Kulkanya

Hypoxic pneumonia is a major cause of morbidity and mortality among children in low- and middle-income countries. This study evaluated 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PCV10) effectiveness in preventing hypoxic pneumonia among children in Maha Sarakham Province, Thailand. We conducted a retrospective case-control study using medical records from Maha Sarakham Hospital between January 2020 and December 2022. Cases were children aged 1 month to 5 y hospitalized with hypoxic pneumonia; controls were hospitalized with non-hypoxic pneumonia. PCV10 vaccination status (unvaccinated, incomplete [1-2 doses], or complete [≥3 doses]) was compared. Vaccine effectiveness (VE) was estimated using logistic regression, with propensity score adjustment and multiple imputation to address confounding and missing data. Among 398 children hospitalized with pneumonia, 207 (52.0%) had hypoxic pneumonia and 191 (48.0%) had non-hypoxic pneumonia. Overall vaccine coverage was low: 18.3% were fully vaccinated, 3.5% partially vaccinated, and 78.1% unvaccinated. The unadjusted VE against hypoxic pneumonia was 28% (95% CI: 3-55%; P < .001). After propensity score adjustment, VE increased to 31% (95% CI: 8-62%; P < .001). Using multiple imputation, the unadjusted and adjusted VE were 34% (95% CI: 5-61%; P < .001) and 35% (95% CI: 4-65%; P < .001). In conclusion, PCV10 vaccination was associated with a reduced risk of hypoxic pneumonia among Thai children. These findings support the integration of PCVs into national immunization programs and underscore the importance of achieving and maintaining high vaccine coverage to prevent severe pediatric pneumonia.

02 Jun 2026·Microbial Genomics

Clonal expansion of global pneumococcal sequence cluster 3 within serotype 8 after 13-valent pneumococcal conjugate vaccine introduction, South Africa

Article

Author: de Gouveia, Linda ; Lorenz, Oliver ; Cohen, Cheryl ; Meiring, Susan ; McGee, Lesley ; Lekhuleni, Cebile ; von Gottberg, Anne ; Chochua, Sopio ; Quan, Vanessa ; Kleynhans, Jackie ; Cremers, Amelieke J.H. ; Lo, Stephanie W. ; Hawkins, Paulina A. ; du Plessis, Mignon ; Cheng, Hsueh-Chien R. ; Ndlangisa, Kedibone ; Bentley, Stephen D. ; Sanches Ferreira, Ana D. ; Skosana, Happy

Background . Serotype 8 has emerged as a common non-vaccine serotype causing invasive pneumococcal disease (IPD) in children and adults globally after the introduction of pneumococcal conjugate vaccines (PCV). We aimed to determine serotype 8 incidence and genomic epidemiology in South Africa. Methods . From national, laboratory-based surveillance for IPD in South Africa, we calculated the incidence of serotype 8 and global pneumococcal sequence cluster 3 (GPSC3) before and after PCV introduction. We performed phylodynamic analysis of genomes from clonal complex (CC) 53 and described South African isolates in the context of a global collection of serotype 8 and GPSC3 genomes. Results. Compared to the pre-PCV period, serotype 8 incidence increased in the late-PCV13 period among children <5 years [incidence rate ratio (IRR) 2.3, 95% confidence interval (CI) 1.3–4.1] and adults >64 years (2.8, 1.1–8.3). Similarly, GPSC3 rates increased among children <5 years (IRR 2.4, 95% CI 1.4–4.3) and individuals of all ages (1.7, 1.3–2.1). Serotype 8 CC53 population dynamics predicted at least five clonal expansions since the most recent common ancestor in 1929 (credible interval 1919–1937), with future predictions showing increases in the effective population size despite remaining largely susceptible to first-line treatment. Serotype 8 CC53 isolates from South Africa had a clonal structure when contextualized within a global collection of serotype 8 and GPSC3 genomes. Conclusion. Serotype 8 invasive disease incidence increased in South Africa after PCV introduction. Predictions showed sustained increases over time. Since South Africa switched to a lower-valency PCV10 (Pneumosil, Serum Institute of India) that does not include serotype 8 in 2024, continued surveillance will be crucial to inform PCV policy-making.

01 Jun 2026·Journal of Infection and Public Health

Baseline epidemiology study of nasopharyngeal carriage and serotypes of Streptococcus pneumoniae in children aged 6–59 months prior to the introduction of pneumococcal conjugate vaccine in Iran

Article

Author: Tajmehrabi Namini, Parinaz ; Sadat Larijani, Mona ; Abdollahi, Sara ; Haji Maghsoudi, Saiedeh ; Esteghamati, Abdoulreza ; Sayyahfar, Shirin ; Rohani, Mahdi ; Azimi, Leila ; Moradi, Ladan ; Bavand, Anahita ; Karimi, Abdollah ; Fahimzad, Alireza ; Eybpoosh, Sana ; Ashrafian, Fatemeh ; Pournasiri, Zahra ; Rafiei Tabatabaei, Sedigheh ; Sorouri, Rahim ; Velayati, Ali Akbar ; Parzadeh, Masoumeh ; Zali, Mahsan ; Doroud, Delaram ; Ramezannejad, Mojgan ; Banifazl, Mohammad ; Ramezani, Amitis

BACKGROUND AND AIM:

This study aimed to assess the prevalence, serotype distribution, and antimicrobial susceptibility of Streptococcus pneumoniae (S. pneumoniae) in children aged 6-59 months in Iran, prior to introducing pneumococcal conjugate vaccine (PCV).

METHODS:

Nasopharyngeal (NP) samples were collected from unvaccinated children aged 6-59 months in this multicenter study. S. pneumoniae was identified using culture methods along with biochemical characteristics and confirmed by real-time PCR. Antibiotic resistance testing was performed utilizing the MIC method. Serotyping was accomplished through the utilization of the Quellung test.

RESULTS:

Of the 1063 nasopharynx isolates, 20.4% carried pneumococcus in NP. The five most common isolated serotypes were 23 F, 19 F, 14, 15B and 6 A. High frequency of 15B, as non-vaccine serotypes (NVTs), was observed. Approximately 20% of the isolates were non-susceptible to penicillin, while low resistance rates were recorded against ceftriaxone (8.7%). Overall, 25.4% of pneumococcal strains exhibited multidrug resistance (MDR). The serotype coverage of PCV7, PCV10, and PCV13 were determined as 42.5%, 54.7%, and 61.8%, respectively.

CONCLUSIONS:

S. pneumoniae was detected in 20.4% Iranian children's NP samples, with the serotype 23 F dominancy. Emerging of 15B and lower PCVs prediction coverage compared to other unvaccinated countries, might stem from limited administration of PCV13, environmental/epidemiological factors, and COVID-19-related shifts in colonization. Ongoing surveillance of pneumococcal carriage, serotype distribution, and antimicrobial resistance are required due to the existence of antibiotic resistance and MDR isolates.

News (Medical) associated with Pneumococcal Polysaccharide Conjugate Vaccine(Glaxosmithkline Plc)

18 Mar 2025

·www.globenewswire.com

Curevo Raises $110 Million to Advance Amezosvatein Shingles Vaccine

-- Amezosvatein has shown excellent immunogenicity and improved tolerability in Phase 2 study -- Medicxi leads round, joined by new investors OrbiMed, HBM Healthcare Investments, and Sanofi Ventures -- Former Chair of GSK’s vaccine business and Chief Scientific Advisor to Operation Warp Speed, Moncef Slaoui, to join Curevo as Board Chair March 17, 2025 -- Curevo Vaccine (Curevo), a privately-held clinical-stage biotechnology company dedicated to developing varicella zoster virus (VZV) vaccines with improved tolerability, today announces the closing of a $110 million Series B round to advance development of amezosvatein, its vaccine for shingles. Leading the round is new investor Medicxi, a European biotech-focused investment firm with significant experience investing in vaccine companies such as Vaxcyte and ViceBio. Joining Medicxi is an international group of investment funds including OrbiMed, HBM Healthcare Investments, and Sanofi Ventures plus existing investors RA Capital Management, Janus Henderson Investors, Adjuvant Capital, and founding investor GC Biopharma. “This Series B round will fund the extension of our successful Phase 2 program into an additional 640 participants, including the key population of adults over age 70, to finalize dose selection ahead of the Phase 3 program,” said Curevo’s CEO, George Simeon, MBA/MPH. “Designed based upon feedback from regulators and other stakeholders, this short extension trial will begin mid-2025 and serve to set the company for clinical, strategic, and regulatory success.” Concurrent with the round, Moncef Slaoui, PhD, will join Curevo as Board Chair. Dr. Slaoui was most recently the Chief Scientific Advisor to Operation Warp Speed during the COVID-19 pandemic, helping deliver vaccines against the SARS-CoV-2 virus. He spent nearly 30 years at GlaxoSmithKline, during which he helped shape its vaccine business by contributing to the creation of numerous new vaccines including Shingrix® (shingles), Cervarix® (HPV-induced cervical cancer), Mosquirix® (malaria), Rotarix® (rotavirus gastroenteritis), and Synflorix® (pneumococcal disease). “I have been collaborating with the Curevo team for several weeks now,” stated Dr. Slaoui. “I’m very excited to work with them to help perfect shingles vaccination, adding good tolerability to the exceptional efficacy achieved by the current vaccine. The data so far show Curevo’s adjuvant technology has the attributes to succeed in this endeavor.” Also joining Curevo’s Board of Directors will be Giovanni Mariggi, PhD, co-founder and Partner at Medicxi, an experienced infectious disease investor and board member. “Patients, doctors, and payors are very clear a new shingles vaccine like amezosvatein would be welcome in the global marketplace. Amezosvatein’s activity and improved tolerability profile could allow it to be a significant product in the shingles vaccines market. We are excited to support Curevo’s plan with a streamlined path to approval,” stated Dr. Mariggi. Tal Zaks, MD/PhD, will be joining Curevo’s Board of Directors on behalf of OrbiMed. Dr. Zaks is the former Chief Medical Officer of Moderna, where he led development of their mRNA vaccine against the SARS-CoV-2 virus. He previously held senior leadership positions in drug development at GSK and Sanofi. “OrbiMed has a long history of investing in biotech companies like Curevo seeking to improve healthcare outcomes while creating long-term shareholder value,” said Dr. Zaks. “The fact amezosvatein contains an optimized version of the TLR4 agonist with a known mechanism of action reduces biological risk while providing the competitive advantage of potentially improved tolerability, which should position it as the first choice for people who want to be protected from shingles.” ‘Amezosvatein’ is the assigned non-proprietary name for CRV-101, a non-mRNA adjuvanted subunit vaccine under investigation by Curevo. Like Shingrix, amezosvatein uses a subunit protein antigen called glycoprotein ‘E’ (gE). Targeting the gE antigen is proven to elicit a long-term, protective immune response to prevent shingles. Amezosvatein’s adjuvant contains an optimized version of the TLR4 agonist proven by Shingrix to be biologically active in shingles vaccination. Amezosvatein was engineered to maintain exceptional efficacy and have a best-in-class tolerability profile. The SLA-SE adjuvant formulation was developed at Seattle-based Access to Advanced Health Institute (AAHI) and amezosvatein was licensed from the Mogam Institute for Biomedical Research, a research institute funded by South Korea’s GC Biopharma. Curevo is a privately held, clinical-stage biotechnology company based near Seattle dedicated to reducing the burden of infectious disease by developing vaccines with improved tolerability and accessibility. Curevo’s lead product is amezosvatein, a non-mRNA adjuvanted sub-unit vaccine to prevent shingles, a serious medical condition involving a painful, blistering skin rash where 10-18% of people also develop serious, long-lasting nerve pain. The current $4+ billion shingles vaccine market is characterized by accessibility issues and vaccine hesitancy/dose avoidance related to vaccine tolerability. For more information visit https://curevovaccine.com/. Medicxi is a healthcare-focused investment firm with the mission to create and invest in companies across the full drug development continuum. Leveraging deep expertise in drug development and company creation spanning over two decades, Medicxi invests in early and late-stage therapeutics with a product vision that can fulfill a clear unmet medical need. For more information, please visit: https://www.medicxi.com. OrbiMed is a leading global healthcare investment firm with approximately $17 billion in assets under management. OrbiMed invests globally across the healthcare industry, from start-ups to large multinational corporations, via private equity funds, public equity funds, and royalty/credit funds. OrbiMed seeks to be a capital provider of choice, providing tailored financing solutions and extensive global team resources to help build world-class healthcare companies. OrbiMed’s team of over 100 professionals is based in New York City, London, San Francisco, Shanghai, Hong Kong, Mumbai, Herzliya, and other key global markets. For more information, please visit www.orbimed.com. Switzerland-based HBM Healthcare Investments focuses on the healthcare sector, holding and managing an international portfolio of promising companies in the human medicine, biotechnology, medical technology, diagnostics, and related areas. Many of these companies have their lead products already available on the market or are at an advanced stage of development. The portfolio companies are closely tracked and actively guided in their strategic direction. This is what makes HBM Healthcare Investments an interesting alternative to investments in big pharma and biotechnology companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (SIX:HBMN). Sanofi Ventures is the corporate venture capital arm of Sanofi, focused on investing in promising early-stage healthcare companies. The firm supports pioneering innovations in biotechnology, digital health, and life sciences aligning with Sanofi’s mission to bring life-changing treatments to patients worldwide. For more information, please visit www.sanofiventures.com. Founded in 2004, RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare, life sciences, and planetary health companies. RA Capital creates and funds innovative companies, from private seed rounds to public follow-on financings, allowing management teams to drive value creation from inception through commercialization and beyond. RA Capital's knowledge engine is guided by its TechAtlas internal research division, and Raven, RA Capital's healthcare incubator, offers entrepreneurs and innovators a collaborative and comprehensive platform to explore the novel and the re-imagined. RA Capital has more than 150 employees and over $10 billion in assets under management. Janus Henderson Investors exists to help clients achieve their long-term financial goals. Its active management offers clients the opportunity to outperform passive portfolios over the course of market cycles. With more than 360 investment professionals, Janus Henderson Investors provides access to some of the industry’s most talented and innovative thinkers, spanning equities, fixed income, multi-asset, and alternatives, globally. Its investment teams blend insight, originality, and precision with rigorous analysis, structured processes, and robust risk management. Janus Henderson Investors builds client partnerships on openness and trust, channeling expertise from across the business and communicating the views of its experts in a timely and relevant way. https://www.janushenderson.com/ Headquartered in New York, with offices in Zürich, Adjuvant is a global life science investment fund built to accelerate the development of new technologies for the world's most pressing public health challenges. Backed by prominent healthcare and emerging market investors, Adjuvant draws upon its network of scientists, public health experts, biopharmaceutical industry veterans, and development finance professionals to identify new investment opportunities. Adjuvant invests in companies developing promising new vaccines, therapeutics, diagnostics, and medical devices targeting high-burden infectious diseases, maternal and child health, antimicrobial resistance, and malnutrition, with a commitment to make these interventions accessible globally. For more information, visit http://www.adjuvantcapital.com Founding investor GC Biopharma (formerly known as Green Cross Corporation) is a biopharmaceutical company headquartered in Yongin, South Korea. The company has over half a century of experience in the development and manufacturing of plasma derivatives and vaccines and expanded its global presence with the successful USA market entry of ALYGLO™ (intravenous immunoglobulin G) in 2024. In line with its mission to meet the demands of future healthcare, GC Biopharma continues to drive innovation by leveraging its core R&D capabilities in engineering of proteins, mRNAs, and lipid nanoparticle (LNP) drug delivery platforms to develop therapeutics for the field of rare disease as well as I&I (Immunology & Inflammation). To learn more about the company, visit https://www.gcbiopharma.com/eng/ The content above comes from the network. if any infringement, please contact us to modify.

Vaccine

04 Feb 2025

·ir.arcturusrx.com

Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate

SAN DIEGO --(BUSINESS WIRE)--Feb. 4, 2025-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced the appointment of Moncef Slaoui , Ph.D., as Chair Designate. Dr. Slaoui has been serving on the Company’s Board of Directors since June 2024 . “Dr. Moncef Slaoui has a long-proven track record in the pharmaceutical and biotechnology industry, and we are delighted to have him as our Chair Designate,” said Joseph Payne , President & Chief Executive Officer of Arcturus. “We look forward to working with him as we enter a transformative year of advancing our pipeline of therapeutics and vaccines.” “Arcturus has deep expertise in mRNA delivery for therapeutics and a validated commercial stage vaccines platform,” said Dr. Moncef Slaoui . “I am excited to work with the company during this potentially transformational time with multiple key data readouts across its pipeline.” About Dr. Moncef Slaoui Dr. Moncef Slaoui was most recently the Chief Scientific Advisor to Operation Warp Speed. Under his leadership the operation enabled the fastest ever development, manufacturing, and approval of multiple COVID-19 vaccines in less than 11 months after the virus genetic sequence was described. Dr. Slaoui has sat on several biotechnology company boards, including Moderna, Inc. and Lonza Group AG , and he chaired the boards of Galvani, and Vaxcyte, a vaccine development platform company. Dr. Slaoui spent nearly 30 years at GlaxoSmithKline (GSK) holding leadership positions including as member of the Board of Directors of GSK PLC; Chairman of Pharmaceutical R&D; Chairman Global R&D, Vaccines & Oncology; and Chairman, Global Vaccines. As Chairman of Pharmaceutical R&D, Dr. Slaoui led a redesign of GSK’s R&D structure and culture to improve focus on innovation and productivity. As Chairman of Global Vaccines, Dr. Slaoui was directly involved in GSK's vaccine pipeline, leading to the creation of 14 new vaccines, including Shingrix®, to prevent shingles; Cervarix®, to prevent cervical cancer; Mosquirix, to prevent malaria; Rotarix®, to prevent rotavirus gastroenteritis; and Synflorix, to prevent pneumococcal disease. In 2016, Dr. Slaoui was recognized as one of Fortune's 50 Greatest World Leaders for his work in under-researched diseases common in the developing world. He served on the Advisory Committee to the Director of the NIH from 2011 to 2016 and has advised the U.S. President's Council of Advisors on Science and Technology . Dr. Slaoui holds a Ph.D. in Molecular Biology and Immunology from the Université Libre de Bruxelles , completed postdoctoral studies at Harvard Medical School and Tufts University School of Medicine , and was a Professor of Immunology at the University of Mons , Belgium . He received an accelerated Master of Business Administration from IMD, Switzerland in 1998. About Arcturus Founded in 2013 and based in San Diego, California , Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a commercial mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA Technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed KOSTAIVE®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan , ARCALIS , focused on the manufacture of mRNA vaccines and therapeutics. Arcturus’ pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (over 400 patents and patent applications in the U.S. , Europe , Japan , China , and other countries). For more information, visit www.ArcturusRx.com. In addition, please connect with us on Twitter and LinkedIn. View source version on businesswire.com: https://www.businesswire.com/news/home/20250204663825/en/ Arcturus Therapeutics Public Relations & Investor Relations Neda Safarzadeh VP, Head of IR/PR/Marketing (858) 900-2682 IR@ArcturusRx.com Source: Arcturus Therapeutics Holdings Inc.

VaccineExecutive ChangemRNA

08 Jan 2025

·abzena.com

Abzena Strengthens Board with Appointment of Biopharma Industry Leader, Dr Moncef Slaoui

San Diego, CA, January 8, 2025 – Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, has today announced the appointment of Moncef Slaoui, PhD, to its Board of Directors. A highly accomplished leader in the biopharmaceutical industry with over 40 years’ experience, Dr Slaoui has held numerous executive leadership and board level positions, to help drug development companies through high phases of growth. Matt Stober, Former CEO of Abzena said, “Dr Slaoui’s exceptional track record of leadership and expertise in product innovation will be extremely valuable as we continue to grow and position ourselves as the leading drug development and manufacturing organization for complex biologics and bioconjugates. We welcome him to our board and look forward to leveraging his extensive experience in supporting high‐growth pharmaceutical businesses.” “I am thrilled to be joining Abzena’s Board of Directors,” said Slaoui. “Abzena is a true innovator in the CRO and CDMO space, and I look forward to helping them develop new technologies and platforms that enable the better delivery of next gen therapeutics.” “I am delighted that Moncef has accepted this position,” said Geoffrey Glass, Chairman of Abzena’s Board. “Moncef brings a set of highly relevant skills and experience to the board, and I look forward to working with him and our executive team as we support Abzena through its next stage of growth.” Dr Moncef Slaoui currently serves as an advisor to Medicxi and is on the Board of Directors of several companies including Cedar Health, Arcturus Therapeutics, Altesa, Zephyr AI and Vicebio. He has previously sat on biotechnology company boards for Moderna, Inc., Lonza Group AG, Galvani, and Vaxcyte. During the COVID-19 pandemic, he served as the Chief Scientific Advisor to Operation Warp Speed, where his leadership enabled the fastest manufacturing, approval and deployment of multiple COVID-19 vaccines in the US. Dr Slaoui spent three decades of his career at GlaxoSmithKline (GSK), where he held several senior leadership positions, including being a member of the Board of Directors of GSK PLC, Chairman of Pharmaceutical R&D, Chairman Global R&D, Vaccines & Oncology, and Chairman, Global Vaccines. During his tenure, he led GSK’s Pharmaceutical R&D restructuring to improve its focus on innovation and productivity and was directly involved in the development of 14 new vaccines, including Shingrix, Cervarix, Mosquirix, Rotarix®, and Synflorix. Moncef holds a PhD in Molecular Biology and Immunology from the Université Libre de Bruxelles and completed his postdoctoral studies at Harvard Medical School and Tufts University. He also has an accelerated MBA from IMD in Switzerland.

VaccineExecutive Change

100 Deals associated with Pneumococcal Polysaccharide Conjugate Vaccine(Glaxosmithkline Plc)

External Link

KEGG	Wiki	ATC	Drug Bank
D10601	Pneumococcal Polysaccharide Conjugate Vaccine(Glaxosmithkline Plc)	J07AL52	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Otitis Media	Japan	GSK Plc	17 Apr 2015
Pneumococcal Infections	Japan	Japan Vaccine Co., Ltd.	26 Mar 2015
Pneumonia	Canada	GSK Plc	22 May 2009
Acute otitis media	European Union	GlaxoSmithKline Biologicals SA	29 Mar 2009
Acute otitis media	Iceland	GlaxoSmithKline Biologicals SA	29 Mar 2009
Acute otitis media	Liechtenstein	GlaxoSmithKline Biologicals SA	29 Mar 2009
Acute otitis media	Norway	GlaxoSmithKline Biologicals SA	29 Mar 2009
invasive Streptococcus pneumoniae infection	European Union	GlaxoSmithKline Biologicals SA	29 Mar 2009
invasive Streptococcus pneumoniae infection	Iceland	GlaxoSmithKline Biologicals SA	29 Mar 2009
invasive Streptococcus pneumoniae infection	Liechtenstein	GlaxoSmithKline Biologicals SA	29 Mar 2009
invasive Streptococcus pneumoniae infection	Norway	GlaxoSmithKline Biologicals SA	29 Mar 2009

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pneumonia, Pneumococcal	Phase 3	Mexico	GSK Plc	03 Jul 2007
Community Acquired Pneumonia	Phase 3	Argentina	GSK Plc	28 Jun 2007
Community Acquired Pneumonia	Phase 3	Colombia	GSK Plc	28 Jun 2007
Community Acquired Pneumonia	Phase 3	Panama	GSK Plc	28 Jun 2007
Streptococcal Infections	Phase 3	Philippines	GSK Plc	07 Aug 2006
Streptococcal Infections	Phase 3	Poland	GSK Plc	07 Aug 2006

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00624819 (CTgov)	Phase 3	Pneumonia, Pneumococcal	524	GSK1024805A+Varilrix+Infanrix hexa+Havrix (Synflorix + Infanrix + Havrix and/or Varilrix Group)	yvpssziofh = cezcrcqcoe xkjpxowilt (vmhpnbaoqg, qzlccahkyw - exjjopnipt) View more	-	18 Mar 2020
				Varilrix+Infanrix hexa+Havrix+Prevenar (Prevenar + Infanrix + Havrix and/or Varilrix Group)	yvpssziofh = akxhusivgc xkjpxowilt (vmhpnbaoqg, fcpbkcyufa - daslhgvvia) View more
NCT01027845 (CTgov)	Phase 3	Streptococcal Infections	360	Pneumococcal vaccine GSK1024850A+DTPa (10Pn Group)	vqefwxpftr(hqqymaofme) = ctyberapyo hvqtpuuwia (gdwiewqzbh, tgsakbwmpp - ncbaharkob) View more	-	29 Nov 2019
				DTPa (DTPa Group)	vqefwxpftr(hqqymaofme) = upqceqdjsg hvqtpuuwia (gdwiewqzbh, grwrsnlyil - fitneolerc) View more
NCT01175083 (CTgov)	Phase 3	Streptococcal Infections	300	GSK1024850A+Tritanrix-HepB/Hib+Polio Sabin (Tritanrix-HepB/Hib+Polio Sabin <6S Group)	zwvcztfefd(popoyzrkmm) = aahnfrodbg iahabrmrcq (xubicphflp, mhjmqkrkta - ccwztevguo) View more	-	06 Jun 2019
				GSK1024850A+Tritanrix-HepB/Hib+Polio Sabin (Tritanrix-HepB/Hib+Polio Sabin <6NS Group)	zwvcztfefd(popoyzrkmm) = yreerahduy iahabrmrcq (xubicphflp, rhvdliqbyt - qqsvlknhip) View more
NCT00496015 (CTgov)	Phase 3	Streptococcal Infections	750	Pneumococcal conjugate vaccine GSK1024850A.+Paracetamol.+Infanrix hexa. (Synflorix I Group)	rmrmwvcjit = bwubfmlnzm aelhceixva (rnvfdtnpjt, nitnxheipk - lrquwyrnhn) View more	-	18 Jan 2019
				Pneumococcal conjugate vaccine GSK1024850A.+Infanrix hexa. (Synflorix II Group)	rmrmwvcjit = ntfopjvdjt aelhceixva (rnvfdtnpjt, kgetrtxsje - zztiqkaujv) View more
NCT00345358 (CTgov)	Phase 3	Streptococcal Infections	600	Synflorix+Infanrix IPV/Hib (Synflorix <6M Group)	wqgcibmzen = zspygmswgd bgznkmfqjb (frgxlvezev, wvckkvdrka - afpgwlpfbb) View more	-	15 Jan 2019
				Synflorix (Synflorix 7-11M Group)	wqgcibmzen = meecbchxuv bgznkmfqjb (frgxlvezev, jxvlnegqmx - shkilcslyn) View more
NCT00547248 (CTgov)	Phase 3	Streptococcal Infections	756	Synflorix+Tritanrix-HepB+Hiberix+Polio Sabin (Synflorix + Tritanrix -HepB/ Hiberix + Polio Sabin Group)	nefjuumoea = ouftattrgl ewnydlrsak (fxwfvsekto, eemxdhcssz - hkeubbsmfp) View more	-	14 Jan 2019
				Tritanrix-HepB+Hiberix+Polio Sabin+Prevenar (Prevenar + Tritanrix - HepB/ Hiberix + Polio Sabin Group)	nefjuumoea = snblmimyam ewnydlrsak (fxwfvsekto, kmbfirvkbj - gseqvyjuiw) View more
NCT00390910 (CTgov)	Phase 3	Pneumococcal Infections	286	Pneumococcal conjugate vaccine GSK1024850A+Infanrix hexa (Synflorix™ + Infanrix™ Hexa Group III)	ctxbxmivxv = apctavagii iefdbnawie (gnqcgqlmrs, jegkcbtfwo - hknatlgakg) View more	-	17 Dec 2018
				Pneumococcal conjugate vaccine GSK1024850A+Infanrix hexa (Synflorix™ + Infanrix™ Hexa Group I)	xnhxeomubv = djfwqzyilj msegxhpmqw (gkuruvjvbq, gfsdybxrpw - aogjprusfg) View more
NCT00652951 (CTgov)	Phase 3	Streptococcal Infections	780	GSK Biologicals´ Pneumococcal Conjugate Vaccine GSK1024850A (Synflorix™)+Infanrix™ hexa. (Synflorix + Infanrix Hexa Group)	vfeecuxsxx(qjaxomhmiq) = vlksxogvma aiujzomsge (ffogvawqty, ppwzknswot - eicsoaodhh) View more	-	14 Dec 2018
				GSK Biologicals´ Pneumococcal Conjugate Vaccine GSK1024850A (Synflorix™)+Pediacel™ (Synflorix + Pediacel Group)	vfeecuxsxx(qjaxomhmiq) = admautwiwi aiujzomsge (ffogvawqty, wkdrkhuhjh - osleeswczn) View more
NCT00985465 (CTgov)	Phase 3	Streptococcal Infections	218	Synflorix (Synflorix Primed Group)	rcrsdkzfes = rmdglunjjf fwgxkjjshj (ophuwamqut, sfzkccxcmb - ousopuwkff) View more	-	14 Dec 2018
				Synflorix™ vaccine (Synflorix Unprimed Group)	djtmycwxej = vgxdvusnnj saaaviwuoa (izhvkflqbn, zuwoxkwpaw - zndpkwikfk) View more
NCT00370396 (CTgov)	Phase 3	Streptococcal Infections	1,200	Synflorix+Infanrix hexa (Synflorix-Synflorix Group)	ypnrjyorrc = npleygnyng nqqlocikoe (vtiqixfmur, ovhsjmghop - gvzcdecjuu) View more	-	26 Nov 2018
				Infanrix hexa+Prevenar (Prevenar-Prevenar Group)	ypnrjyorrc = hkqlzcpmdo nqqlocikoe (vtiqixfmur, lcvicvyrvk - rgabwfxizc) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis